Cargando…

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Schjesvold, Fredrik, Richardson, Paul G., Facon, Thierry, Alegre, Adrián, Spencer, Andrew, Jurczyszyn, Artur, Sunami, Kazutaka, Frenzel, Laurent, Min, Chang-Ki, Guillonneau, Sophie, Lin, Peggy L., Le-Guennec, Solenn, Campana, Frank, van de Velde, Helgi, Bensfia, Samira, Bringhen, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Errata Corrige
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883557/ https://www.ncbi.nlm.nih.gov/pubmed/35229573 http://dx.doi.org/10.3324/haematol.2021.279160

Ejemplares similares

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
por: Martin, Tom, et al.
Publicado: (2022)

This corrects the article “Kikuchi-Fujimoto Disease in the Unites States: Three Case Reports and Review of the Literature” in volume 6, e2014001, link: http://www.mjhid.org/article/view/11988
Publicado: (2014)

“Eating and Nutrition Habits in Young Competitive Athletes: A Comparison Between Soccer Players and Cyclists”
por: Galanti, G., et al.
Publicado: (2014)

Errata corrige
Publicado: (2019)

Errata
Publicado: (2018)

Genetic platelet depletion is superior in platelet transfusion compared to current models
por: Salzmann, Manuel, et al.
Publicado: (2020)

Errata
Publicado: (2020)

Errata
Publicado: (2020)

Errata corrige
Publicado: (2019)

Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE)
por: Nikkilä, Atte, et al.
Publicado: (2020)

Low-dose ionizing radiations leave scars on human hematopoietic stem and progenitor cells: the role of reactive oxygen species
por: Yamashita, Masayuki, et al.
Publicado: (2021)

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
por: Beksac, Meral, et al.
Publicado: (2021)

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers
por: Hrdinová, Johana, et al.
Publicado: (2021)

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research
por: Lazaryan, Aleksandr, et al.
Publicado: (2021)

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
por: Gaymes, Terry J, et al.
Publicado: (2021)

Errata
Publicado: (2022)

ERRATA CORRIGE
Publicado: (2021)

ERRATA CORRIGE
Publicado: (2022)

ERRATA CORRIGE
Publicado: (2022)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2022)

ERRATA CORRIGE
Publicado: (2023)

ERRATA CORRIGE
Publicado: (2023)

ARID5B influences B-cell development and function in mouse
por: Goodings, Charnise, et al.
Publicado: (2023)

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
por: Kloos, Robin Q.H., et al.
Publicado: (2023)

ERRATA CORRIGE
Publicado: (2023)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone
por: Thai, Hoai‐Thu, et al.
Publicado: (2021)

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES
por: Perrot, Aurore, et al.
Publicado: (2023)

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma
por: Rachedi, Fatiha, et al.
Publicado: (2022)

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
por: Djebbari, Faouzi, et al.
Publicado: (2022)

Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome
por: Richardson, Paul G., et al.
Publicado: (2021)

Bélanger S, Tu MM, Rahim MM, et al. Impaired natural killer cell self-education and “missing-self” responses in Ly49-deficient mice. Blood. 2012;120(3):592-602.
Publicado: (2013)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS
por: Quach, H., et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
por: Spicka, Ivan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_642e5bvhsq5f0fssumkv3pm5dd